Pharmacologic inhibition of L-tyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU)

Journal of Inherited Metabolic Disease

Volumn 37, Issue 5, 2014, Pages 735-743

  Harding, Cary O ^a   Winn, Shelley R ^a   Gibson, K Michael ^b   Arning, Erland ^c   Bottiglieri, Teodoro ^c   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMINO ACID; CYCLOHEXANONE DERIVATIVE; DOPAMINE; ENZYME INHIBITOR; NITISINONE; NITROBENZOIC ACID DERIVATIVE; TYROSINE;

ANIMAL; BRAIN CHEMISTRY; C57BL MOUSE; DEFICIENCY; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHENYLKETONURIA;

AMINO ACIDS; ANIMALS; BRAIN CHEMISTRY; CYCLOHEXANONES; DOPAMINE; ENZYME INHIBITORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROTRANSMITTER AGENTS; NITROBENZOATES; PHENYLKETONURIAS; TYROSINE;

EID: 84893166740     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-013-9675-2     Document Type: Article

References (29)

1. Azen CG, Koch R et al (1991) Intellectual development in 12-year-old children treated for phenylketonuria. Am J Dis Child 145(1):35–39
2. Batshaw ML, Valle D et al (1981) Unsuccessful treatment of phenylketonuria with tyrosine. J Pediatr 99(1):159–160
3. Choi TB, Pardridge WM (1986) Phenylalanine transport at the human blood–brain barrier. Studies with isolated human brain capillaries. J Biol Chem 261(14):6536–6541
4. Christ S, Huijbregts S et al (2010) Executive function in early-treated phenylketonuria: profile and underlying mechanisms. Mol Genet Metab 99(Suppl 1):S22–S32
5. Christensen HN, Streicher JA et al (1948) Effects of feeding individual amino acids upon the distribution of other amino acids between cells and extracellular fluid. J Biol Chem 172(2):515–524
6. De Groot MJ, Hoeksma M et al (2010) Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab 99(Suppl 1):S86–S89
7. Feillet F, Van Spronsen FJ et al (2010) Challenges and pitfalls in the management of phenylketonuria. Pediatrics 126(2):333–341
8. Harding C (2008) Progress toward cell-directed therapy for phenylketonuria. Clin Genet 74(2):97–104
9. Harding CO, Wild K et al (1998) Metabolic engineering as therapy for inborn errors of metabolism - development of mice with phenylalanine hydroxylase expression in muscle. Gene Ther 5(5):677–683
10. Introne WJ, Perry MB et al (2011) A 3-Year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 103(4):307–314
11. Kanai Y, Segawa H et al (1998) Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4f2 antigen (Cd98). J Biol Chem 273(37):23629–23632
12. Koshimura K, Miwa S et al (1990) Enhancement of dopamine release in vivo from the rat striatum by dialytic perfusion of 6r-L-erythro-5,6,7,8-tetrahydrobiopterin. J Neurochem 54(4):1391–1397
13. Lindstedt S, Holme E et al (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340(8823):813–817
14. Lou HC, Lykkelund C et al (1987) Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria. Acta Paediatr Scand 76(4):560–565
15. Lykkelund C, Nielsen JB et al (1988) Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine. Eur J Pediatr 148(3):238–245
16. Mastroberardino L, Spindler B et al (1998) Amino-acid transport by heterodimers of 4f2hc/Cd98 and members of a Permease family. Nature 395(6699):288–291
17. Matalon R, Michals-Matalon K et al (2006) Large neutral amino acids in the treatment of phenylketonuria (Pku). J Inherit Metab Dis 29(6):732–738
18. McDonald JD, Bode VC et al (1990) Pahhph-5: a mouse mutant deficient in phenylalanine hydroxylase. Proc Natl Acad Sci U S A 87(5):1965–1967
19. Miyamoto M, Fitzpatrick T (1957) Competitive inhibition of mammalian tyrosinase by phenylalanine and its relationship to hair pigmentation in phenylketonuria. Nature 179(4552):199–200
20. Ogburn KD, Bottiglieri T et al (2006) Prostaglandin J2 reduces Catechol-O-Methyltransferase activity and enhances dopamine toxicity in neuronal cells. Neurobiol Dis 22(2):294–301
21. Pascucci T, Ventura R et al (2002) Deficits in brain serotonin synthesis in a genetic mouse model of phenylketonuria. Neuroreport 13(18):2561–2564
22. Pascucci T, Andolina D et al (2009) 5-hydroxytryptophan rescues serotonin response to stress in prefrontal cortex of hyperphenylalaninaemic mice. Int J Neuropsychopharmacol 12(8):1067–1079
23. Pietz J, Kreis R et al (1999) Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest 103(8):1169–1178
24. Puglisi-Allegra S, Cabib S et al (2000) Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. Neuroreport 11(6):1361–1364
25. Slocum RH, Cummings JG (1991) Amino acid analysis of physiological samples. In: Hommes FA (ed) Techniques in diagnostic human biochemical genetics: A laboratory manual. Wiley-Liss, New York, pp 87–126
26. Thompson AJ, Smith I et al (1990) Neurological deterioration in young adults with phenylketonuria. Lancet 336:602–605
27. Vanzutphen KH, Packman W et al (2007) Executive functioning in children and adolescents with phenylketonuria. Clin Genet 72(1):13–18
28. Vogel KR, Arning E et al (2013) Non-physiological amino acid (Npaa) therapy targeting brain phenylalanine reduction: pilot studies in Pahenu2 mice. J Inherit Metab Dis 36(3):513–523
29. Walter JH, White FJ (2004) Blood phenylalanine control in adolescents with phenylketonuria. Int J Adolesc Med Health 16(1):41–45